TL;DR: The Centers for Medicare & Medicaid Services modified NCD 222 governing home blood glucose monitor coverage, with an effective date of March 7, 2026. Here's what billing teams need to know before submitting DME claims.

CMS home blood glucose monitor coverage policy under NCD 222 has been updated. This policy controls Medicare reimbursement for home blood glucose monitors billed as durable medical equipment (DME). No specific HCPCS codes are listed in this version of the policy document — but the coverage criteria and patient eligibility conditions that drive claim approval are clearly defined, and your billing team needs to know them cold.


Quick-Reference Table

Field Detail
Payer Centers for Medicare & Medicaid Services (CMS)
Policy Home Blood Glucose Monitors — NCD 222
Policy Code NCD 222
Change Type Modified
Effective Date 2026-03-07
Impact Level Medium
Specialties Affected Endocrinology, Primary Care, DME Suppliers, Ophthalmology (visually impaired patients)
Key Action Audit all active home blood glucose monitor claims and patient files to confirm all three eligibility conditions are documented before March 7, 2026

CMS Home Blood Glucose Monitor Coverage Criteria and Medical Necessity Requirements 2026

NCD 222 is the National Coverage Determination governing Medicare coverage of home blood glucose monitors for diabetic patients who use them in the home setting. The Centers for Medicare & Medicaid Services classifies these devices under the durable medical equipment benefit category.

To meet medical necessity under this coverage policy, three conditions must all be present and documented in the patient record:

#Covered Indication
1The patient has a confirmed diabetes diagnosis.
2The patient's physician states the patient can be trained to use the specific prescribed device correctly — or documents that a responsible caregiver can be trained to do so on the patient's behalf.
3The device is designed for home use, not clinical use.

All three conditions are required. Missing documentation on any one of them is enough to trigger a claim denial. This is where most billing teams run into trouble — the physician attestation for condition two is frequently absent from the file.

The policy also draws a clear line between clinical-grade and home-use devices. Reflectance colorimeter devices used in clinical settings are not covered as DME for home use. CMS excludes them because they require frequent professional recalibration, which makes them unsuitable for unsupervised home use. If your DME supplier is billing for clinical-grade monitors under home-use codes, that exposure needs to be resolved before the effective date.

Medical necessity documentation must support that the patient needs to check blood glucose frequently. The policy ties coverage to a clinical rationale: frequent home monitoring allows the patient to contact their physician for timely treatment adjustments. That clinical rationale needs to be in the chart — not just the order.

This coverage policy does not mention prior authorization as a specific requirement at the NCD level. However, your Medicare Administrative Contractor may impose prior authorization requirements through a local coverage determination. Check with your MAC before assuming prior auth is not needed.


CMS Home Blood Glucose Monitor Exclusions and Non-Covered Indications

CMS is direct about what does not qualify under NCD 222.

Clinical reflectance colorimeter devices are excluded. These are the professional-grade meters designed for use in labs and clinical settings. They need regular professional recalibration. CMS does not cover them as home DME, regardless of the patient's diagnosis.

A device that does not meet the "designed for home use" standard fails condition three automatically. The clinical design of the device — not just how the patient is using it — determines eligibility. A meter issued from a clinical supply chain and recalibrated by staff does not become a home-use device because it left the building.

Patients who have not been diagnosed with diabetes are not covered. The diagnosis requirement is non-negotiable. A patient managing pre-diabetes or monitoring glucose for another condition does not meet condition one under this policy.


Coverage Indications at a Glance

Indication Status Relevant Codes Notes
Diabetic patient using home-designed blood glucose monitor Covered Not specified in policy document All three eligibility conditions must be documented
Diabetic patient with caregiver trained to operate device Covered Not specified in policy document Physician must document caregiver arrangement in the record
Visually impaired diabetic patient using adapted monitor Covered Not specified in policy document Physician must certify visual impairment is severe enough to require the special system; higher reimbursement rate applies
+ 4 more indications

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

This policy is now in effect (since 2026-03-12). Verify your claims match the updated criteria above.

CMS Home Blood Glucose Monitor Billing Guidelines and Action Items 2026

Blood glucose monitor billing under NCD 222 is not complicated in concept, but it breaks down in execution. Documentation gaps and device classification errors are the two biggest sources of claim denial under this policy. Here's what to fix before March 7, 2026.

#Action Item
1

Audit your active patient files for all three eligibility conditions. Pull every open DME claim or order for home blood glucose monitors. Confirm the chart shows a diabetes diagnosis, a physician statement on the patient's ability to use the device (or caregiver documentation), and confirmation that the device is home-use grade. If any condition is missing, get the documentation before billing.

2

Verify the device classification before it hits the claim. If your DME supplier stocks both clinical and home-use meters, make sure your ordering and charge capture process separates them clearly. A clinical-grade device billed as home DME will not meet condition three. Build that check into your intake workflow now.

3

Document the caregiver arrangement explicitly when applicable. When a patient cannot operate the device themselves, the physician must document that a responsible individual has been trained and is monitoring the patient. A vague note does not satisfy this requirement. The record needs to name the arrangement and confirm the physician's oversight role.

+ 4 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

If your organization supplies monitors to a high volume of diabetic patients and you have not audited your documentation practices recently, talk to your compliance officer before March 7, 2026. The three-condition rule is clear, but real-world documentation rarely matches policy language without deliberate effort.


Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

CPT, HCPCS, and ICD-10 Codes for Home Blood Glucose Monitors Under NCD 222

This policy document does not list specific CPT or HCPCS codes. CMS has not published specific code assignments within the NCD 222 policy text as updated on March 7, 2026.

What This Means for Billing Teams

The absence of explicit codes in the policy does not reduce your exposure — it increases it. Without CMS naming the exact codes, your billing team must rely on the HCPCS code set for DME, your MAC's local coverage determination, and your DME supplier's code assignment practices.

The standard HCPCS codes used for home blood glucose monitors and supplies are assigned at the claim level by DME billers, but NCD 222 itself does not enumerate them. Your MAC's LCD is the authoritative source for which codes apply in your region.

Request the current applicable HCPCS codes from your DME supplier or MAC directly. Do not assume the codes in your charge capture are current without confirming against your MAC's LCD database.


Get the Full Picture

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee